66 results on '"DI Napoli D"'
Search Results
2. INTERVENTIONAL NEURORADIOLOGY: PRELIMINARY STUDY
- Author
-
Attanasio, C, Castaldo, S, Di, Napoli D, Gonzalez, E, Ferrara, D, Gallinaro, O, Cozzolino, C S, De, Marinis P, and Muto, M Ospedale
- Published
- 2006
3. Oxidative damage and cytotoxic cell involvement in the neuronal pathogenesis of mucopolysaccharidosis IIIB
- Author
-
VILLANI, GUGLIELMO ROSARIO DOMENI, DI NATALE, PAOLA, Di Domenico C., Musella A., Cecere F., Di Napoli D., European Study Group on Lysosomal Diseases (ESGLD) Workshop, Villani, GUGLIELMO ROSARIO DOMENI, Di Domenico, C., Musella, A., Cecere, F., Di Napoli, D., and DI NATALE, Paola
- Subjects
pathogenesi ,neurodegeneration ,Mucopolysaccharidosis IIIB - Abstract
Mucopolysaccharidosis IIIB (MPS IIIB) is a lysosomal storage disease due to mutations in the gene encoding alpha-N-acetylglucosaminidase and is characterized by a severe neurological disorder. Although several studies have been reported for the murine model of the disease, the molecular basis and the sequence of events leading to neurodegeneration remain to be clarified. We previously suggested the possible involvement of the reactive oxygen species, namely the superoxide ion produced by the microglial NADPH oxidase complex, in the disease pathogenesis (Villani et al, 2007). In the present study we extended the analysis of oxidative stress by evaluating the production of superoxide ions throughout the CNS and by evaluating the effect of the stress on the cellular macromolecules. These approaches applied to one-month-old, three-month-old and six-month-old mice revealed that oxidative stress is present in the affected cerebrum and cerebellum tissues from one month from birth, mainly in the rostral region (208 % compared to normal control), and that it results primarily in protein oxidation, with lipid peroxidation, and especially DNA oxidation, appearing milder and restricted essentially to the cerebellum. Our findings show that oxidative stress and all the analyzed stress-related pathological changes occurr very early in the disease course, most likely before one month of age. We also identified additional genes possibly associated with the neuropathology of MPS IIIB disease. Real time RT-PCR analysis revealed an altered expression of the Sod1, Ret, Bmp4, Tgfb, Gzmb and Prf1 genes. Since Gzmb and Prf1 are proteins secreted by NK/cytotoxic T-cells, these data suggest the involvement of cytotoxic cells in the neuronal pathogenesis.
- Published
- 2009
4. Lentiviral vector-mediated gene therapy for Sanfilippo B syndrome (MPS IIIB)
- Author
-
VILLANI, GUGLIELMO ROSARIO DOMENI, DI NATALE, PAOLA, DI DOMENICO C., GARGIULO N., FOLLENZI A., NALDINI L., DI NAPOLI D., CASTALDO S., GONZALEZ E., DE FELICE M., MITHBAOKAR P., III International Conference 'Prospects in the Treatment of Rare Diseases', Villani, GUGLIELMO ROSARIO DOMENI, DI DOMENICO, C., Gargiulo, N., Follenzi, A., Naldini, L., DI NAPOLI, D., Castaldo, S., Gonzalez, E., DE FELICE, M., Mithbaokar, P., and DI NATALE, Paola
- Published
- 2004
5. Gene therapy of Sanfilippo type B syndrome using a lentiviral vector
- Author
-
VILLANI, GUGLIELMO ROSARIO DOMENI, DI NATALE, PAOLA, DI NAPOLI D., CASTALDO S., GONZALEZ E., GARGIULO N., DE FELICE M., MITHBAOKAR P., FOLLENZI A., NALDINI L., European Study Group on Lysosomal Diseases (ESGLD), Villani, GUGLIELMO ROSARIO DOMENI, DI NAPOLI, D., Castaldo, S., Gonzalez, E., Gargiulo, N., DE FELICE, M., Mithbaokar, P., Follenzi, A., Naldini, L., and DI NATALE, Paola
- Published
- 2003
6. Intracranial gene delivery of LV-NAGLU vector corrects neuropathology in murine MPS IIIB
- Author
-
Di Domenico C, Villani GR, Di Napoli D, Nusco E, Calì G, Nitsch L, and Di Natale P.
- Abstract
Mucopolysacccharidosis (MPS) IIIB is an inherited lysosomal storage disorder caused by the deficiency of alpha-N-acetylglucosaminidase (NAGLU). The disease is characterized by mild somatic features and severe neurological involvement with high mortality. Although several therapeutic approaches have been applied to the murine model of the disease, no effective therapy is available for patients. In this study, we used the lentiviral-NAGLU vector to deliver the functional human NAGLU gene into the brain of young adult MPS IIIB mice. We report the restoration of active enzyme with a sustained expression throughout a large portion of the brain, and a significantly improved behavioral performance of treated animals. Moreover, we analyzed the effect of therapy on the expression profile of some genes related to neurotrophic signaling molecules and inflammatory cytokines previously found altered in MPS IIIB mice. At 1 month from treatment, the level of cerebellin 1 (Cbln1) was decreased while the brain-derived neurotrophic factor (Bdnf) expression was increased, both reaching normal values. At 6 months from treatment a significant reduction in the expression of all the inflammation- and oxidative stress-related genes was observed, as well as the maintenance of the correction of the Bdnf gene expression. These results indicate that NAGLU delivery from intracerebral sources has the capacity to alleviate most disease manifestations in MPS IIIB mice; furthermore, Bdnf might be a response-to-therapy biomarker for MPS IIIB.
- Published
- 2009
7. A swine liver transplatation model of ischemia/reperfusion injury: protective effects of the heme oxygenase-1 products
- Author
-
Scuderi, V., Giuliani, Antonio, Andria, B., Alimenti, E., Tammaro, A., Scala, S., Attanasio, C., Corona, M., Di Napoli, D., Castaldo, S., Pantaleo, A., and Calis, F.
- Published
- 2008
8. Significant increased metabolic function and reduced apoptotic index in marginal isolated and perfused pig liver pretreated with CO and biliverdin
- Author
-
Scuderi, V., Di Florio, E., Musumeci, A., Bracco, A., Mezza, E., Andria, B., Attanasio, C., Castaldo, S., Di Napoli, D., Giuliani, Antonio, Pantaleo, D., and Calise, F.
- Published
- 2006
9. Scattering by a planar junction between two lossy slabs in radiopropagation environments
- Author
-
DI NAPOLI, D, Ferrara, Flaminio, Gennarelli, Claudio, and Riccio, Giovanni
- Published
- 2006
10. A UAPO solution for the field diffracted by a lossy dielectric half-plane
- Author
-
DI NAPOLI, D, Gennarelli, Claudio, Migliozzi, Massimo, and Riccio, Giovanni
- Published
- 2006
11. Biliverdin Protects against Liver Ischemia Reperfusion Injury in Swine
- Author
-
Andria, B, Bracco, A, Attanasio, C, Castaldo, S, Cerrito, M, Cozzolino, S, Di Napoli, D, Giovannoni, R, Mancini, A, Musumeci, A, Mezza, E, Nasti, M, Scuderi, V, Staibano, S, Lavitrano, M, Otterbein, L, Calise, F, Calise, F., CERRITO, MARIA GRAZIA, GIOVANNONI, ROBERTO, LAVITRANO, MARIALUISA, Andria, B, Bracco, A, Attanasio, C, Castaldo, S, Cerrito, M, Cozzolino, S, Di Napoli, D, Giovannoni, R, Mancini, A, Musumeci, A, Mezza, E, Nasti, M, Scuderi, V, Staibano, S, Lavitrano, M, Otterbein, L, Calise, F, Calise, F., CERRITO, MARIA GRAZIA, GIOVANNONI, ROBERTO, and LAVITRANO, MARIALUISA
- Abstract
Ischemia reperfusion injury (IRI) in organ transplantation remains a serious and unsolved problem. Organs that undergo significant damage during IRI, function less well immediately after reperfusion and tend to have more problems at later times when rejection can occur. Biliverdin has emerged as an agent that potently suppress IRI in rodent models. Since the use of biliverdin is being developed as a potential therapeutic modality for humans, we tested the efficacy for its effects on IRI of the liver in swine, an accepted and relevant pre-clinical animal model. Administration of biliverdin resulted in rapid appearance of bilirubin in the serum and significantly suppressed IRI-induced liver dysfunction as measured by multiple parameters including urea and ammonia clearance, neutrophil infiltration and tissue histopathology including hepatocyte cell death. Taken together, our findings, in a large animal model, provide strong support for the continued evaluation of biliverdin as a potential therapeutic in the clinical setting of transplantation of the liver and perhaps other organs.
- Published
- 2013
12. 134 A SWINE LIVER TRANSPLANTATION MODEL OF ISCHEMIA/REPERFUSION INJURY: PROTECTIVE EFFECTS OF THE HEME OXYGENASE-1 PRODUCTS
- Author
-
Scuderi, V., primary, Giuliani, A., additional, Andria, B., additional, Alimenti, E., additional, Tammaro, A., additional, Scala, S., additional, Attanasio, C., additional, Corona, M., additional, Di Napoli, D., additional, Castaldo, S., additional, Pantaleo, A., additional, and Calise, F., additional
- Published
- 2008
- Full Text
- View/download PDF
13. Wave propagation through walls and windows: a UAPO based approach
- Author
-
Di Napoli, D., primary, Ferrara, F., additional, Gennarelli, C., additional, and Riccio, G., additional
- Published
- 2007
- Full Text
- View/download PDF
14. A UAPO Based Model for Predicting the Field Propagation Near a Tunnel Entrance
- Author
-
Di Napoli, D., primary, Ferrara, F., additional, Gennarelli, C., additional, and Riccio, G., additional
- Published
- 2007
- Full Text
- View/download PDF
15. A method for predicting the scattering by a lossy wedge in automotive radio propagation environments
- Author
-
Di Napoli, D., primary, Ferrara, F., additional, Gennarelli, C., additional, and Riccio, G., additional
- Published
- 2006
- Full Text
- View/download PDF
16. Building Corner Scattering Prediction Using a UAPO Solution for the Diffraction Contribution.
- Author
-
Di Napoli, D., Ferrara, F., Gennarelli, C., and Riccio, G.
- Published
- 2006
- Full Text
- View/download PDF
17. Human CD34+ stem cells produce bone nodules in vivo.
- Author
-
Graziano, A., d'Aquino, R., Laino, G., Proto, A., Giuliano, M. T., Pirozzi, G., De Rosa, A., Di Napoli, D., and Papaccio, G.
- Subjects
STEM cells ,DENTAL pulp ,BONE regeneration ,IMMUNOFLUORESCENCE ,X-ray diffraction ,TRANSPLANTATION of organs, tissues, etc. - Abstract
Objectives: The aim of this study was to select and provide enough stem cells for quick transplantation in bone engineering procedures, avoiding any in vitro expansion step. Materials and Methods: Dental germ pulp, collected from 25 healthy subjects aged 13–20 years, were subjected to magnetic-activated cell sorting to select a CD34
+ stem cell population capable of differentiating into pre-osteoblasts. These cells were allowed to adhere to an absorbable polylactic–coglycolic acid scaffold for 30 min, without any prior expansion, and the CD34+ cell-colonized scaffolds were then transplanted into immunocompromised rats, subcutaneously. Results: After 60 days, analysis of recovered transplants revealed that they were formed of nodules of bone, of the same dimensions as the original scaffold. Bone-specific proteins were detected by immunofluorescence, within the nodules, and X-ray diffraction patterns revealed characteristic features of bone. In addition, presence of platelet endothelial cell adhesion molecule and von Willebrand factor immunoreactivity were suggestive of neo-angiogenesis and neovasculogenesis taking place within nodules. Importantly, these vessels were HLA-1+ and, thus, clearly human in origin. Conclusions: This study indicates that CD34+ cells obtained from dental pulp can be used for engineering bone, without the need for prior culture expanding procedures. Using autologous stem cells, this schedule could be used to provide the basis for bone regenerative surgery, with limited sacrifice of tissue, low morbidity at the collection site, and significant reduction in time needed for clinical recovery. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
18. Home care for patients with ictus cerebri. An observational study in the metropolitan area of Milano | L'assistenza domiciliare ai pazienti colpiti da ictus cerebrale. Studio osservazionale nell'ambito della città di Milano
- Author
-
Agnes, F., Di Napoli, D., Bertolaia, P., Fabbrini, S., Mapelli, V., Cereda, D., Silvana Castaldi, Tagliata, S., and Auxilia, F.
19. Limited Transgene Immune Response and Long-Term Expression of Humanα-L-Iduronidase in Young Adult Mice with Mucopolysaccharidosis Type I by Liver-Directed Gene Therapy
- Author
-
Angelo Lombardo, E. Gonzalez Y Reyero, P. Di Natale, Luigi Naldini, C. Di Domenico, D. Di Napoli, Di Domenico, C, Di Napoli, D, Reyero, Egy, Lombardo, ANGELO LEONE, Naldini, Luigi, Di Natale, P., DI DOMENICO, C, DI NAPOLI, D, GONZALEZ Y., REYERO E, Lombardo, A, Naldini, L, and DI NATALE, Paola
- Subjects
medicine.medical_specialty ,Time Factors ,Mucopolysaccharidosis I ,Genetic enhancement ,Transgene ,Genetic Vectors ,Spleen ,Biology ,Polymerase Chain Reaction ,Viral vector ,Iduronidase ,Mice ,Mucopolysaccharidosis type I ,Immune system ,Internal medicine ,Gene expression ,Genetics ,medicine ,Animals ,Humans ,Transgenes ,Molecular Biology ,Autoantibodies ,Lentivirus ,Genetic Therapy ,Molecular biology ,Recombinant Proteins ,medicine.anatomical_structure ,Endocrinology ,Liver ,Organ Specificity ,Antibody Formation ,biology.protein ,Molecular Medicine ,Antibody - Abstract
Mucopolysaccharidosis type I (MPS I) due to deficient alpha-L-iduronidase (IDUA) activity results in the accumulation of glycosaminoglycans (GAGs) in many of the cells of affected patients. Stable gene replacement by in vivo administration of lentiviral vectors (LVs) has therapeutic potential for metabolic disorders and other systemic diseases. We have previously shown in a murine model the therapeutic potential of lentiviral IDUA vector-mediated gene therapy, in which human IDUA cDNA was driven by the cytomegalovirus promoter. However, the major limitation of this approach was the induction of an immune response against the therapeutic protein, which limited the efficacy and long-term duration of treatment. In this study, we evaluate the potential of liver-directed gene therapy, that is, programming of murine hepatocytes to secrete the enzyme with mannose 6-phosphate (M6P), which can be taken up by distant cells. Eight- to 10-week-old mice were injected via the tail vein with a lentiviral vector expressing human IDUA cDNA driven by the albumin gene promoter selectively expressed in hepatocytes. One month after treatment, IDUA activity was present in the liver and spleen of treated mice; an expression level of 1% normal IDUA activity was sufficient to reduce the GAG level in liver, spleen, kidney, heart, and lung. Interestingly, 6 months after a single injection of this vector, IDUA activity was detectable in several murine tissues; the level of enzyme activity was low but sufficient to maintain the decrease in GAG levels in liver, spleen, kidney, heart, and lung. Also, the level of enzyme-specific antibodies reached at 6 months postinjection was nearly null, and real-time polymerase chain reaction analysis showed high levels of vector DNA content in liver and spleen. Thus, these results show that the use of LV with the albumin gene promoter selectively expressed in hepatocytes limited the immune response to the transgene and allowed stable and prolonged expression of the IDUA enzyme and a partial correction of the pathology.
- Published
- 2006
20. Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study
- Author
-
Fabio Ciceri, Valentina Canti, Davide Di Napoli, Marta D'Amico, Giacomo Giacalone, Moreno Tresoldi, Valentina Sofia, Luisa Roveri, Paolo Scarpellini, Rebecca De Lorenzo, Patrizia Rovere-Querini, Emanuele Bosi, Elena Brioni, Chiara Lanzani, Francesco Benedetti, Alberto Ambrosio, Antonella Castagna, Alberto Zangrillo, Caterina Conte, Mario Gennaro Mazza, Giovanni Landoni, De Lorenzo, R., Conte, C., Lanzani, C., Benedetti, F., Roveri, L., Mazza, M. G., Brioni, E., Giacalone, G., Canti, V., Sofia, V., D'Amico, M., Di Napoli, D., Ambrosio, A., Scarpellini, P., Castagna, A., Landoni, G., Zangrillo, A., Bosi, E., Tresoldi, M., Ciceri, F., and Rovere-Querini, P.
- Subjects
Male ,Viral Diseases ,Critical Care and Emergency Medicine ,Pulmonology ,Aftercare ,Cardiovascular Medicine ,Vascular Medicine ,Stress Disorders, Post-Traumatic ,Medical Conditions ,Endocrinology ,0302 clinical medicine ,Interquartile range ,Medicine and Health Sciences ,Coronary Heart Disease ,Dyspnea ,COVID-19 ,Diabetes mellitus ,Malnutrition ,Critical care and emergency medicine ,Oxygen ,Post-traumatic stress disorder ,Cognitive impairment ,030212 general & internal medicine ,Cognitive Impairment ,Multidisciplinary ,Cognitive Neurology ,Post-Traumatic Stress Disorder ,Middle Aged ,Anxiety Disorders ,Infectious Diseases ,Neurology ,Cardiovascular Diseases ,Medicine ,Female ,Coronavirus Infections ,Research Article ,Cohort study ,medicine.medical_specialty ,Respiratory rate ,Endocrine Disorders ,Science ,Cognitive Neuroscience ,Pneumonia, Viral ,Cardiology ,Neuropsychiatric Disorders ,Neuroses ,Respiratory Disorders ,03 medical and health sciences ,Internal medicine ,Mental Health and Psychiatry ,Diabetes Mellitus ,medicine ,Humans ,Cognitive Dysfunction ,Pandemics ,Aged ,Nutrition ,business.industry ,Biology and Life Sciences ,Covid 19 ,Emergency department ,Odds ratio ,Confidence interval ,Blood pressure ,Metabolic Disorders ,Cognitive Science ,business ,Body mass index ,030217 neurology & neurosurgery ,Follow-Up Studies ,Neuroscience - Abstract
Data on residual clinical damage after Coronavirus disease-2019 (COVID-19) are lacking. The aims of this study were to investigate whether COVID-19 leaves behind residual dysfunction, and identify patients who might benefit from post-discharge monitoring. All patients aged ≥18 years admitted to the Emergency Department (ED) for COVID-19, and evaluated at post-discharge follow-up between 7 April and 7 May, 2020, were enrolled. Primary outcome was need of follow-up, defined as the presence at follow-up of at least one among: Respiratory rate (RR) >20 breaths/min, uncontrolled blood pressure (BP) requiring therapeutic change, moderate to very severe dyspnoea, malnutrition, or new-onset cognitive impairment, according to validated scores. Post-traumatic stress disorder (PTSD) served as secondary outcome. 185 patients were included. Median [interquartile range] time from hospital discharge to follow-up was 23 [20-29] days. 109 (58.9%) patients needed follow-up. At follow-up evaluation, 58 (31.3%) patients were dyspnoeic, 41 (22.2%) tachypnoeic, 10 (5.4%) malnourished, 106 (57.3%) at risk for malnutrition. Forty (21.6%) patients had uncontrolled BP requiring therapeutic change, and 47 (25.4%) new-onset cognitive impairment. PTSD was observed in 41 (22.2%) patients. At regression tree analysis, the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) and body mass index (BMI) at ED presentation, and age emerged as independent predictors of the need of followup. Patients with PaO2/FiO2
- Published
- 2020
21. A rat model of acute kidney injury through systemic hypoperfusion evaluated by micro-US, color and PW-Doppler
- Author
-
Francesca Nettuno, Luca Brunese, Teresa Segreto, Daniele Di Napoli, Marco Montella, Francesca Iacobellis, Roberto Grassi, Salvatore Cappabianca, S. Cozzolino, Daniela Berritto, Raffaele Natella, Iacobellis, F., Segreto, T., Berritto, D., Nettuno, F., Cozzolino, S., Di Napoli, D., Montella, M., Natella, R., Cappabianca, S., Brunese, L., and Grassi, R.
- Subjects
Male ,Mean arterial pressure ,medicine.medical_specialty ,Ischemia ,Reproducibility of Result ,Shock, Hemorrhagic ,Kidney ,030218 nuclear medicine & medical imaging ,Rats, Sprague-Dawley ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,Animals ,Hypopharyngeal Neoplasm ,Radiology, Nuclear Medicine and imaging ,Animal model ,Ultrasonography, Doppler, Color ,Hemorrhagic shock ,Hypoperfusion ,Kidney injury ,Renal blood flow ,Hypopharyngeal Neoplasms ,Renal ischemia ,Animal ,business.industry ,Acute kidney injury ,Echogenicity ,Reproducibility of Results ,Ultrasonography, Doppler ,General Medicine ,Acute Kidney Injury ,medicine.disease ,Rats ,Disease Models, Animal ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cardiology ,Rat ,business ,Perfusion - Abstract
Aim To create an animal model of acute renal ischemia induced by systemic hypoperfusion, controllable and reproducible to study, in real time, hemorrhagic shock changes with micro-imaging.Animals and methods Hemorrhagic shock was induced in rats activating a syringe pump setup to remove 1 mL/min of blood, through the femoral artery catheter. The withdrawal was continued until the mean arterial pressure (MAP) dropped to 25-30 mmHg. For the next 60 min, the MAP was maintained at a constant pressure value, by automatic pump infusion and withdrawal. Micro-ultrasound imaging was performed using the Vevo 2100 system with the MS250 transducer (13-24 MHz). Renal size, morphology and echogenicity were evaluated in B-mode. Renal blood flow was evaluated using color and PW-Doppler.Results After 1 h of ischemia, B-mode images documented slight changes in kidney echogenicity. Color and PW-Doppler analysis showed a reduction in renal blood flow in kidneys during the hypoperfusion with a progressive and significant change from baseline values of resistive index (RI). At the histological evaluation, 60 min of hypoperfusion resulted in ischemic changes in the kidneys.Conclusions The results of this experimental study encourage the use of the described model to study acute renal ischemia trough severe hypoperfusion. The histological data confirmed that the model was able to produce injury in renal parenchyma. It can be used to assess acute ischemic damage not only in the kidney but also in other organs by using all available dedicated small animals imaging techniques.
- Published
- 2018
22. Worsening of Cardiomyopathy Using Deflazacort in an Animal Model Rescued by Gene Therapy
- Author
-
Fabio Russo, Alessio Lancioni, Elvira De Leonibus, Vincenzo Nigro, Gerardo Nigro, Ida Luisa Rotundo, Vincenzo Russo, S. Castaldo, Giulio Piluso, Carmen Vitiello, Daniele Di Napoli, Stefania Faraso, Alberto Auricchio, Rotundo, Il, Faraso, S, De Leonibus, E, Nigro, G, Vitiello, C, Lancioni, A, Di Napoli, D, Castaldo, S, Russo, V, Russo, F, Piluso, G, Auricchio, Alberto, Nigro, V., Nigro, Gerardo, Piluso, Giulio, Auricchio, A, and Nigro, Vincenzo
- Subjects
Male ,Heredity ,Duchenne muscular dystrophy ,Genetic enhancement ,medicine.medical_treatment ,Cardiomyopathy ,lcsh:Medicine ,030204 cardiovascular system & hematology ,Cardiovascular ,Muscular Dystrophies ,0302 clinical medicine ,Pregnenediones ,Cricetinae ,lcsh:Science ,Multidisciplinary ,Ejection fraction ,biology ,Gene Therapy ,Genomics ,Animal Models ,Neuromuscular Diseases ,Dependovirus ,3. Good health ,Phenotypes ,Neurology ,Echocardiography ,Medicine ,Cardiomyopathies ,medicine.drug ,Research Article ,Cardiac function curve ,medicine.medical_specialty ,Intraperitoneal injection ,Blotting, Western ,Genetic Vectors ,03 medical and health sciences ,Model Organisms ,Genomic Medicine ,Internal medicine ,Sarcoglycans ,medicine ,Genetics ,Animals ,Biology ,Heart Failure ,Mesocricetus ,business.industry ,lcsh:R ,Human Genetics ,Genetic Therapy ,medicine.disease ,biology.organism_classification ,Deflazacort ,Endocrinology ,lcsh:Q ,business ,030217 neurology & neurosurgery - Abstract
We have previously demonstrated that gene therapy can rescue the phenotype and extend lifespan in the delta-sarcoglycan deficient cardiomyopathic hamster. In patients with similar genetic defects, steroids have been largely used to slow down disease progression. Aim of our study was to evaluate the combined effects of steroid treatment and gene therapy on cardiac function. We injected the human delta-sarcoglycan cDNA by adeno-associated virus (AAV) 2/8 by a single intraperitoneal injection into BIO14.6 Syrian hamsters at ten days of age to rescue the phenotype. We then treated the hamsters with deflazacort. Treatment was administered to half of the hamsters that had received the AAV and the other hamsters without AAV, as well as to normal hamsters. Both horizontal and vertical activities were greatly enhanced by deflazacort in all groups. As in previous experiments, the AAV treatment alone was able to preserve the ejection fraction (7067% EF). However, the EF value declined (52614%) with a combination of AAV and deflazacort. This was similar with all the other groups of affected animals.We confirmthat gene therapy improves cardiac function in the BIO14.6 hamsters. Our results suggest that deflazacort is ineffective and may also have a negative impact on the cardiomyopathy rescue, possibly by boosting motor activity. This is unexpected and may have significance in terms of the lifestyle recommendations for patients. We have previously demonstrated that gene therapy can rescue the phenotype and extend lifespan in the delta-sarcoglycan deficient cardiomyopathic hamster. In patients with similar genetic defects, steroids have been largely used to slow down disease progression. Aim of our study was to evaluate the combined effects of steroid treatment and gene therapy on cardiac function. We injected the human delta-sarcoglycan cDNA by adeno-associated virus (AAV) 2/8 by a single intraperitoneal injection into BIO14.6 Syrian hamsters at ten days of age to rescue the phenotype. We then treated the hamsters with deflazacort. Treatment was administered to half of the hamsters that had received the AAV and the other hamsters without AAV, as well as to normal hamsters. Both horizontal and vertical activities were greatly enhanced by deflazacort in all groups. As in previous experiments, the AAV treatment alone was able to preserve the ejection fraction (70±7% EF). However, the EF value declined (52±14%) with a combination of AAV and deflazacort. This was similar with all the other groups of affected animals. We confirm that gene therapy improves cardiac function in the BIO14.6 hamsters. Our results suggest that deflazacort is ineffective and may also have a negative impact on the cardiomyopathy rescue, possibly by boosting motor activity. This is unexpected and may have significance in terms of the lifestyle recommendations for patients. © 2011 Rotundo et al.
- Published
- 2011
23. Activation of stress kinases in the brain of mucopolysaccharidosis IIIB mice
- Author
-
Daniele Di Napoli, Francesca Boscia, Paola Di Natale, Carmela Di Domenico, Francesca Cecere, Cecere, Francesca, Di Domenico, C., Di Napoli, D., Boscia, Francesca, and DI NATALE, Paola
- Subjects
MAPK/ERK pathway ,Mucopolysaccharidosis ,Biology ,p38 Mitogen-Activated Protein Kinases ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Mice ,Mucopolysaccharidosis III ,Cortex (anatomy) ,medicine ,mucopolysaccharidosi ,Animals ,Mitogen-Activated Protein Kinase 8 ,Cells, Cultured ,Cerebral Cortex ,Mice, Knockout ,Neurons ,Mitogen-Activated Protein Kinase 3 ,Kinase ,Neurodegeneration ,Age Factors ,neurodegeneration ,mucopolysaccharidosis ,Heparan sulfate ,medicine.disease ,Molecular biology ,Mice, Mutant Strains ,Disease Models, Animal ,Oxidative Stress ,medicine.anatomical_structure ,chemistry ,Gene Expression Regulation ,Cerebral cortex ,Mitogen-Activated Protein Kinases ,Reactive Oxygen Species ,knockout mouse ,Research Article - Abstract
The accumulation of heparan sulfate (HS) in lysosomes is the primary consequence of the enzyme defect (α-N-acetylglucosaminidase) in mucopolysaccharidosis type IIIB. This accumulation triggers a cascade of pathological events that progressively leads to CNS pathology. Here we examined the activation of the three major stress kinases in the neuronal tissue of a murine model of the disease. ERK1/2 was significantly higher in the cortex of 1–2-month-old affected animals compared with wild-type (Wt) littermates. Similarly, ERK1/2 was stimulated in neurons cultured from MPS IIIB mice. SAPK/JNK was also found to be activated in the cortex of 1–2-month-old affected animals compared with Wt subjects, and the same was found for cultured neurons. In contrast, the active form of p38MAPK was lower in the cortex of 1-month-old MPS IIIB mice compared with Wt animals, but no significant difference was found between the two p38MAPK analyzed in normal and affected neurons cultured in vitro. These data indicate the possible involvement of MAPK dysregulation in the early stage of MPS IIIB brain disease. © 2011 Wiley-Liss, Inc.
- Published
- 2010
24. Intracranial gene delivery of LV-NAGLU vector corrects neuropathology in murine MPS IIIB
- Author
-
Lucio Nitsch, Carmela Di Domenico, Edoardo Nusco, Gaetano Calì, Paola Di Natale, Guglielmo R. D. Villani, Daniele Di Napoli, Di Domenico, C., Villani, GUGLIELMO ROSARIO DOMENI, Di Napoli, D., Nusco, E., Calì, G., Nitsch, Lucio, and DI NATALE, Paola
- Subjects
Genetic enhancement ,Mucopolysaccharidosis ,Genetic Vectors ,Gene delivery ,Injections ,Proinflammatory cytokine ,Mice ,Mucopolysaccharidosis III ,mucopolysaccharidosis • Sanfilippo syndrome type B • gene therapy ,Transduction, Genetic ,Neurotrophic factors ,Acetylglucosaminidase ,Genetics ,Animals ,Medicine ,Genetics (clinical) ,Mice, Knockout ,biology ,business.industry ,Lentivirus ,Genetic transfer ,Gene Transfer Techniques ,Brain ,Genetic Therapy ,medicine.disease ,Immunology ,biology.protein ,Biomarker (medicine) ,business ,Neurotrophin - Abstract
Mucopolysacccharidosis (MPS) IIIB is an inherited lysosomal storage disorder caused by the deficiency of alpha-N-acetylglucosaminidase (NAGLU). The disease is characterized by mild somatic features and severe neurological involvement with high mortality. Although several therapeutic approaches have been applied to the murine model of the disease, no effective therapy is available for patients. In this study, we used the lentiviral-NAGLU vector to deliver the functional human NAGLU gene into the brain of young adult MPS IIIB mice. We report the restoration of active enzyme with a sustained expression throughout a large portion of the brain, and a significantly improved behavioral performance of treated animals. Moreover, we analyzed the effect of therapy on the expression profile of some genes related to neurotrophic signaling molecules and inflammatory cytokines previously found altered in MPS IIIB mice. At 1 month from treatment, the level of cerebellin 1 (Cbln1) was decreased while the brain-derived neurotrophic factor (Bdnf) expression was increased, both reaching normal values. At 6 months from treatment a significant reduction in the expression of all the inflammation- and oxidative stress-related genes was observed, as well as the maintenance of the correction of the Bdnf gene expression. These results indicate that NAGLU delivery from intracerebral sources has the capacity to alleviate most disease manifestations in MPS IIIB mice; furthermore, Bdnf might be a response-to-therapy biomarker for MPS IIIB.
- Published
- 2009
25. Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector
- Author
-
Luigi Naldini, Paola Di Natale, Enrico Gonzalez Y Reyero, Guglielmo R. D. Villani, Angelo Lombardo, Carmela Di Domenico, Daniele Di Napoli, C., DI DOMENICO, Villani, GUGLIELMO ROSARIO DOMENI, D., DI NAPOLI, E. GONZALEZ Y., Reyero, A., Lombardo, L., Naldini, DI NATALE, Paola, Di Domenico, C, Villani, Grd, Di Napoli, D, Reyero, Egy, Lombardo, ANGELO LEONE, Naldini, Luigi, and Di Natale, P.
- Subjects
Genetic enhancement ,Transgene ,Mucopolysaccharidosis ,Mucopolysaccharidosis I ,Genetic Vectors ,Spleen ,Genome, Viral ,Biology ,Mucopolysaccharidosis type I ,Iduronidase ,Mice ,Immune system ,In vivo ,Transduction, Genetic ,Genetics ,medicine ,Animals ,Humans ,Tissue Distribution ,Transgenes ,Molecular Biology ,Glycosaminoglycans ,Kidney ,Homozygote ,Lentivirus ,Genetic Therapy ,medicine.disease ,Molecular biology ,Recombinant Proteins ,Mice, Inbred C57BL ,Disease Models, Animal ,medicine.anatomical_structure ,Liver ,Immunoglobulin G ,Immunology ,Molecular Medicine - Abstract
Mucopolysaccharidosis type I is a lysosomal disease due to mutations in the IDUA gene, resulting in deficiency of alpha- L -iduronidase and accumulation of glycosaminoglycans (GAGs). Bone marrow transplantation and enzyme replacement are two therapies considered only moderately successful for affected patients, making the development of novel treatments necessary. We have previously shown the efficacy of lentivirus-mediated gene transfer to correct patient fibroblasts in vitro. Here we tested lentiviral-IDUA vector gene therapy in vivo on a murine MPS I model. Eight- to 10 week-old mice were injected with increasing lentiviral doses via the tail vein and analyzed 1 month after treatment. A single injection of lentiviral-IDUA vector resulted in transgene expression in several murine tissues, with the highest level reached in liver and spleen. Expression of 1% normal activity was sufficient in treated animals to normalize the GAG level in urine, liver, and spleen and was able to reduce the GAG level in kidney, heart, and lung. Polymerase chain reaction assays showed integration of the viral genome only in liver and spleen of treated animals, suggesting that the correction of the pathology in other tissues was due to secretion into the plasma by liver and spleen and uptake of corrective enzyme by distant tissues. Long-term (6 months) analysis showed the presence of enzyme-specific antibodies and the loss of enzyme activity and vector sequence in the target tissue, suggesting that the transgene-specific immune response interfered with long-term therapeutic correction and led to clearance of transduced cells. In conclusion, our results show the promising potential and the limitations of lentiviral-IDUA vector-mediated gene therapy in an in vivo model.
- Published
- 2005
26. Biliverdin Protects against Liver Ischemia Reperfusion Injury in Swine
- Author
-
Antonio Mancini, Barbara Andria, Antonino Musumeci, S. Castaldo, Santolo Cozzolino, Roberto Giovannoni, Mario Nasti, Chiara Attanasio, Marialuisa Lavitrano, Fulvio Calise, Vincenzo Scuderi, Maria Grazia Cerrito, E. Mezza, Leo E. Otterbein, Daniele Di Napoli, Stefania Staibano, A. Bracco, Andria, B, Bracco, A, Attanasio, C, Castaldo, S, Cerrito, M, Cozzolino, S, Di Napoli, D, Giovannoni, R, Mancini, A, Musumeci, A, Mezza, E, Nasti, M, Scuderi, V, Staibano, S, Lavitrano, M, Otterbein, L, Calise, F, Cerrito, Mg, Musumeci, Antonino, Staibano, Stefania, Otterbein, Le, and Calise, F.
- Subjects
Nephrology ,Pathology ,Anatomy and Physiology ,Swine ,lcsh:Medicine ,Pharmacology ,Ischemia Reperfusion Injury ,protective gene ,pig model ,Organ transplantation ,chemistry.chemical_compound ,0302 clinical medicine ,lcsh:Science ,0303 health sciences ,Multidisciplinary ,Systems Biology ,MED/04 - PATOLOGIA GENERALE ,3. Good health ,Infectious Diseases ,medicine.anatomical_structure ,Liver ,Transplant Surgery ,Reperfusion Injury ,Hepatocyte ,Medicine ,Research Article ,Drugs and Devices ,medicine.medical_specialty ,Histology ,Bilirubin ,Immunology ,Ischemia ,03 medical and health sciences ,Model Organisms ,Internal medicine ,medicine ,Animals ,Biology ,030304 developmental biology ,Transplantation ,Biliverdin ,business.industry ,Biliverdine ,lcsh:R ,Immunologic Subspecialties ,medicine.disease ,chemistry ,Clinical Immunology ,Surgery ,lcsh:Q ,business ,Reperfusion injury ,030217 neurology & neurosurgery - Abstract
Ischemia reperfusion injury (IRI) in organ transplantation remains a serious and unsolved problem. Organs that undergo significant damage during IRI, function less well immediately after reperfusion and tend to have more problems at later times when rejection can occur. Biliverdin has emerged as an agent that potently suppress IRI in rodent models. Since the use of biliverdin is being developed as a potential therapeutic modality for humans, we tested the efficacy for its effects on IRI of the liver in swine, an accepted and relevant pre-clinical animal model. Administration of biliverdin resulted in rapid appearance of bilirubin in the serum and significantly suppressed IRI-induced liver dysfunction as measured by multiple parameters including urea and ammonia clearance, neutrophil infiltration and tissue histopathology including hepatocyte cell death. Taken together, our findings, in a large animal model, provide strong support for the continued evaluation of biliverdin as a potential therapeutic in the clinical setting of transplantation of the liver and perhaps other organs.
- Published
- 2013
27. T.O. 6 Systemic delta-sarcoglycan gene transfer into cardiomyopathic BIO14.6 hamsters by AAV
- Author
-
D. Di Napoli, V. Saccone, N. Sorrentino, S. Castaldo, Giulio Piluso, Vincenzo Nigro, Alberto Auricchio, Carmen Vitiello, Stefania Faraso, S. Aurino, E. Nusco, Vitiello, Adone Carlo, Auricchio, A., Faraso, S., Sorrentino, N., Di Napoli, D., Castaldo, S., Nusco, E., Aurino, S., Saccone, V., Piluso, G., and Nigro, V.
- Subjects
Neurology ,Chemistry ,Pediatrics, Perinatology and Child Health ,Gene transfer ,Neurology (clinical) ,Molecular biology ,Genetics (clinical) ,Delta-Sarcoglycan - Published
- 2006
28. T.O. 6 Systemic delta-sarcoglycan gene transfer into cardiomyopathic BIO14.6 hamsters by AAV
- Author
-
Vitiello, C., Auricchio, A., Faraso, S., Sorrentino, N., Di Napoli, D., Castaldo, S., Nusco, E., Aurino, S., Saccone, V., Piluso, G., and Nigro, V.
- Published
- 2006
- Full Text
- View/download PDF
29. The favourable alliance between CardioMEMS and levosimendan in patients with advanced heart failure.
- Author
-
Visco V, Esposito C, Rispoli A, Di Pietro P, Izzo C, Loria F, Di Napoli D, Virtuoso N, Bramanti A, Manzo M, Vecchione C, and Ciccarelli M
- Subjects
- Humans, Male, Female, Aged, Follow-Up Studies, Treatment Outcome, Hydrazones therapeutic use, Hydrazones administration & dosage, Pyridazines therapeutic use, Pyridazines administration & dosage, Pyridazines economics, Middle Aged, Simendan therapeutic use, Simendan administration & dosage, Heart Failure drug therapy, Heart Failure physiopathology, Quality of Life, Cardiotonic Agents therapeutic use, Cardiotonic Agents administration & dosage
- Abstract
Aims: We report the results of a real-world study based on heart failure (HF) patients' continuous remote monitoring strategy using the CardioMEMS system to assess the impact of this device on healthcare outcomes, costs, and patients' management and quality of life., Methods and Results: We enrolled seven patients (69.00 ± 4.88 years; 71.43% men) with HF, implanted with CardioMEMS, and daily remote monitored to optimize both tailored adjustments of home therapy and/or hospital infusions of levosimendan. We recorded clinical, pharmacological, biochemical, and echocardiographic parameters and data on hospitalizations, emergency room access, visits, and costs. Following the implantation of CardioMEMS, we observed a 50% reduction in the total number of hospitalizations and a 68.7% reduction in the number of days in the hospital. Accordingly, improved patient quality of life was recorded with EQ-5D (pre 58.57 ± 10.29 vs. 1 year post 84.29 ± 19.02, P = 0.008). Echocardiographic data show a statistically significant improvement in both systolic pulmonary artery pressure (47.86 ± 8.67 vs. 35.14 ± 9.34, P = 0.022) and E/e' (19.33 ± 5.04 vs. 12.58 ± 3.53, P = 0.023). The Quantikine® HS High-Sensitivity Kit determined elevated interleukin-6 values at enrolment in all patients, with a statistically significant reduction after 6 months (P = 0.0211). From an economic point of view, the net savings, including the cost of CardioMEMS, were on average €1580 per patient during the entire period of observation, while the analysis performed 12 months after the implant vs. 12 months before showed a net saving of €860 per patient. The ad hoc analysis performed on the levosimendan infusions resulted in 315 days of hospital avoidance and a saving of €205 158 for the seven patients enrolled during the observation period., Conclusions: This innovative strategy prevents unplanned access to the hospital and contributes to the efficient use of healthcare facilities, human resources, and costs., (© 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2024
- Full Text
- View/download PDF
30. Anti-Inflammation and Anti-Oxidation: The Key to Unlocking the Cardiovascular Potential of SGLT2 Inhibitors and GLP1 Receptor Agonists.
- Author
-
Myasoedova VA, Bozzi M, Valerio V, Moschetta D, Massaiu I, Rusconi V, Di Napoli D, Ciccarelli M, Parisi V, Agostoni P, Genovese S, and Poggio P
- Abstract
Type 2 diabetes mellitus (T2DM) is a prevalent and complex metabolic disorder associated with various complications, including cardiovascular diseases. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1-RA) have emerged as novel therapeutic agents for T2DM, primarily aiming to reduce blood glucose levels. However, recent investigations have unveiled their multifaceted effects, extending beyond their glucose-lowering effect. SGLT2i operate by inhibiting the SGLT2 receptor in the kidneys, facilitating the excretion of glucose through urine, leading to reduced blood glucose levels, while GLP1-RA mimic the action of the GLP1 hormone, stimulating glucose-dependent insulin secretion from pancreatic islets. Both SGLT2i and GLP1-RA have shown remarkable benefits in reducing major cardiovascular events in patients with and without T2DM. This comprehensive review explores the expanding horizons of SGLT2i and GLP1-RA in improving cardiovascular health. It delves into the latest research, highlighting the effects of these drugs on heart physiology and metabolism. By elucidating their diverse mechanisms of action and emerging evidence, this review aims to recapitulate the potential of SGLT2i and GLP1-RA as therapeutic options for cardiovascular health beyond their traditional role in managing T2DM.
- Published
- 2023
- Full Text
- View/download PDF
31. Performances of HEART score to predict 6-month prognostic of emergency department patients with chest pain: a retrospective cohort analysis.
- Author
-
Fiore G, Pinto G, Preda A, Rampa L, Gaspardone C, Oppizzi M, Slavich M, Di Napoli D, Bianchi G, Etteri M, Margonato A, and Fragasso G
- Subjects
- Humans, Retrospective Studies, Prognosis, Risk Assessment, Cohort Studies, Electrocardiography, Chest Pain diagnosis, Chest Pain etiology, Emergency Service, Hospital
- Abstract
Background and Importance: Chest pain is a frequent cause of patient admissions in emergency departments (EDs). Clinical scores can help in the management of chest pain patients with an undefined impact on the appropriateness of hospitalization or discharge when compared to usual care., Objectives: The aim of this study was to assess the performances of the HEART score to predict the 6-month prognostic of patients presenting to the ED of a tertiary referral university hospital with non-traumatic chest pain., Design, Settings, and Participants: From 7040 patients presenting with chest pain from 1 January 2015 to 31 December 2017, after applying exclusion criteria (ST-segment elevation >1 mm, shock, absence of telephone number) we selected a sample of 20% chosen randomly. We retrospectively assessed the clinical course, definitive diagnosis, and HEART score according to ED final report. Follow-up was made by telephone interview with discharged patients. In hospitalized patients, clinical records were analyzed to evaluate major adverse cardiac events (MACE) incidence., Outcome Measure and Analysis: The primary endpoint was MACE, comprising cardiovascular death, myocardial infarction, or unscheduled revascularization at 6 months. We assessed the diagnostic performance of the HEART score in ruling out MACE at 6 months. We also assessed the performance of ED usual care in the management of chest pain patients., Results: Of 1119 screened, 1099 were included for analysis after excluding patients lost to follow-up; 788 patients (71.70%) had been discharged and 311 (28.30%) were hospitalized. Incident MACE was 18.3% ( n = 205). The HEART score was retrospectively calculated in 1047 patients showing increasing MACE incidence according to risk category (0.98% for low risk, 38.02% for intermediate risk, and 62.21% for high risk). Low-risk category allowed to safely exclude MACE at 6 months with a negative predictive value (NPV) of 99%. Usual care diagnostic performance showed 97.38% sensitivity, 98.24% specificity, 95.5% positive predictive value, and 99% NPV, with an overall accuracy of 98.00%., Conclusions: In ED patients with chest pain, a low HEART score is associated with a very low risk of MACE at 6 months., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
32. Role of cardiological specialistic evaluation in patients with chest pain presenting in the emergency department.
- Author
-
Fiore G, Di Maio S, Oppizzi M, De Angelis M, Spessot M, Spoladore R, Slavich M, Bianchi G, Setti E, Di Napoli D, Margonato A, and Fragasso G
- Subjects
- Emergency Service, Hospital, Humans, Retrospective Studies, Troponin, Chest Pain diagnosis, Chest Pain etiology, Physicians
- Abstract
Aims: Aim of this study was to evaluate the impact of cardiological and echocardiographic evaluation in addition to a standard clinical and instrumental approach on diagnostic and prognostic accuracy in patients presenting in the emergency department (ED) with chest pain (CP). Acute coronary syndromes, pulmonary embolism and acute aortic syndromes (AAS) (triple-rule-out/TRO) were considered., Methods: From 7040 patients presenting with CP from 1 January 2015 to 31 December 2017, we randomly selected a sample of 1119. We retrospectively evaluated the clinical course and definitive diagnosis according to the ED final report. A 6-month follow-up to assess incident acute cardiovascular events was made by telephone interview in discharged patients; in hospitalized patients, clinical records were analyzed to evaluate the appropriateness of admissions. Diagnostic and prognostic accuracy wasd estimated through sensitivity, specificity, positive (PPV) and negative (NPV) predictive values, according to the presence or absence of cardiological and echocardiographic consultation., Results: Complete information of 1099 patients out of 1119 was retrieved. Seven hundred and eighty-eight patients (71.70%) had been discharged, eight inappropriately (0.73%). Three hundred eleven (28.30%) had been hospitalized, 14 (1.27%) inappropriately. Diagnostic performance showed 97.38% sensitivity, 98.24% specificity, 95.5% PPV and 99% NPV, with an overall accuracy of 98.00%. In patients evaluated by the cardiologist in addition to the ED physician (n = 387) we observed an improvement of sensitivity and NPV at the expense of specificity. Among improperly discharged patients, 7/8 had normal troponin, 7/8 normal ECG and only 1 was evaluated by a cardiologist. Only one inappropriately hospitalized patient was not evaluated by a cardiologist., Conclusions: Early consultation with a cardiologist and echocardiography improves clinical judgment in doubtful cases of CP, increasing diagnostic performance mainly by reducing inappropriate patient discharge and guaranteeing a low rate of inappropriate hospitalizations., (Copyright © 2022 Italian Federation of Cardiology - I.F.C. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
33. Biobanking for COVID-19 research.
- Author
-
Rovere-Querini P, Tresoldi C, Conte C, Ruggeri A, Ghezzi S, DE Lorenzo R, DI Filippo L, Farina N, Ramirez GA, Ripa M, Mancini N, Cantarelli E, Galli L, Poli A, DE Cobelli F, Bonini C, Manfredi AA, Franchini S, Spessot M, Carlucci M, Dagna L, Scarpellini P, Ambrosio A, DI Napoli D, Bosi E, Tresoldi M, Lazzarin A, Landoni G, Martino G, Zangrillo A, Poli G, Castagna A, Vicenzi E, Clementi M, and Ciceri F
- Subjects
- Biological Specimen Banks, Female, Hospitalization, Humans, Male, Middle Aged, SARS-CoV-2, Biomedical Research, COVID-19
- Abstract
Background: Biobanks are imperative infrastructures, particularly during outbreaks, when there is an obligation to acquire and share knowledge as quick as possible to allow for implementation of science-based preventive, diagnostic, prognostic, and therapeutic strategies., Methods: We established a COVID-19 biobank with the aim of collecting high-quality and well-annotated human biospecimens, in the effort to understand the pathogenic mechanisms underlying COVID-19 and identify therapeutic targets (COVID-BioB, NCT04318366). Here we describe our experience and briefly review the characteristics of the biobanks for COVID-19 that have been so far established., Results: A total of 46,677 samples have been collected from 913 participants (63.3% males, median [IQR] age 62.2 [51.2-74.0] years) since the beginning of the program. Most patients (66.9%) had been admitted to hospital for COVID-19, with a median length of stay of 15.0 (9.0-27.0) days. A minority of patients (13.3% of the total) had been admitted for other reasons and subsequently tested positive for SARS-CoV-2. The remainder were managed at home after being seen at the Emergency Department., Conclusions: Having a solid research infrastructure already in place, along with flexibility and adaptability to new requirements, allowed for the quick building of a COVID-19 biobank that will help expand and share the knowledge of SARS-CoV-2.
- Published
- 2022
- Full Text
- View/download PDF
34. A Pilot Study of the Efficacy and Economical Sustainability of Acute Coronavirus Disease 2019 Patient Management in an Outpatient Setting.
- Author
-
De Lorenzo R, Montagna M, Bossi E, Vitali G, Taino A, Cilla M, Pata G, Lazorova L, Pesenti R, Pomaranzi C, Bussolari C, Martinenghi S, Bordonaro N, Di Napoli D, Rizzardini G, Cogliati C, Morici N, and Rovere-Querini P
- Abstract
Objective: To report a preliminary experience of outpatient management of patients with Coronavirus disease 2019 (COVID-19) through an innovative approach of healthcare delivery., Patients and Methods: Patients evaluated at the Mild-to-Moderate COVID-19 Outpatient clinics (MMCOs) of San Raffaele University Hospital and Luigi Sacco University Hospital in Milan, Italy, from 1 October 2020 to 31 October 2021 were included. Patients were referred by general practitioners (GPs), Emergency Department (ED) physicians or hospital specialists (HS) in case of moderate COVID-19. A classification and regression tree (CART) model predicting ED referral by MMCO physicians was developed to aid GPs identify those deserving immediate ED admission. Cost-effectiveness analysis was also performed., Results: A total of 660 patients were included. The majority (70%) was referred by GPs, 21% by the ED and 9% by HS. Patients referred by GPs had more severe disease as assessed by peripheral oxygen saturation (SpO
2 ), ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2 /FiO2 ), C-reactive protein (CRP) levels and interstitial involvement at lung ultrasound. Among them, 18% were addressed to the ED following MMCO assessment. CART analysis identified three independent predictors, namely home-measured SpO2 , age and body mass index (BMI), that robustly divide patients into risk groups of COVID-19 severity. Home-measured SpO2 < 95% and BMI ≥ 33 Kg/m2 defined the high-risk group. The model yielded an accuracy (95% CI) of 83 (77-88)%. Outpatient management of COVID-19 patients allowed the national healthcare system to spare 1,490,422.05 € when compared with inpatient care., Conclusion: Mild-to-moderate COVID-19 outpatient clinics were effective and sustainable in managing COVID-19 patients and allowed to alleviate pressure on EDs and hospital wards, favoring effort redirection toward non-COVID-19 patients., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 De Lorenzo, Montagna, Bossi, Vitali, Taino, Cilla, Pata, Lazorova, Pesenti, Pomaranzi, Bussolari, Martinenghi, Bordonaro, Di Napoli, Rizzardini, Cogliati, Morici and Rovere-Querini.)- Published
- 2022
- Full Text
- View/download PDF
35. Efficacy of a rational algorithm to assess allergy risk in patients receiving the BNT162b2 vaccine.
- Author
-
Yacoub MR, Cucca V, Asperti C, Ramirez GA, Della-Torre E, Moro M, Zandalasini C, Di Napoli D, Ambrosio A, Signorelli C, Colombo S, Beretta L, Ciceri F, Zangrillo A, and Dagna L
- Subjects
- Algorithms, BNT162 Vaccine, COVID-19 Vaccines, Humans, SARS-CoV-2, Anaphylaxis chemically induced, Anaphylaxis diagnosis, Anaphylaxis epidemiology, COVID-19, Vaccines adverse effects
- Abstract
Among 6146 hospital employees, 118 subjects with severe allergic background were identified through a screening questionnaire and stratified into 3 groups (Low-risk (LR), Intermediate (IR) and High-risk (HR) group), based on their allergic anamnesis. Data reports on hypersensitivity reactions (HypR) have been collected in both allergic and non-allergic subjects. Seventeen patients (14%) in the allergic population had a HypR after the first, the second or both doses. Skin manifestations were the most frequent ones. Allergic events were more frequent in HR (35%) than IR (10%; p = 0.005) or LR (0%; p = 0.074) subjects. No patient had anaphylaxis. All patients completed the vaccination schedule. 13 HypR occurred in patients without severe allergic background (13/6028, 0,2%) including one (1/6148, 0.016% of total population) WAO grade-4 anaphylaxis. Our data suggest that BNT162b2 mRNA Covid-19 vaccine is relatively safe also in patients with severe allergic background; however, some precautions are required for high-risk patients., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
36. Stranger Months: How SARS-CoV-2, Fear of Contagion, and Lockdown Measures Impacted Attendance and Clinical Activity During February and March 2020 at an Urban Emergency Department in Milan.
- Author
-
Franchini S, Spessot M, Landoni G, Piani C, Cappelletti C, Mariani F, Mauri S, Taglietti MV, Fortunato M, Furlan F, Guglielmi B, Setti E, Di Napoli D, Borghi G, Pascucci F, Ujlaki-Formenti G, Sannicandro R, Moro M, Colombo S, Dagna L, Castagna A, Tresoldi M, Rovere-Querini P, Ambrosio A, Ciceri F, Zangrillo A, Carlucci M, and Faccincani R
- Subjects
- Communicable Disease Control, Emergency Service, Hospital, Fear, Humans, Retrospective Studies, COVID-19, SARS-CoV-2
- Abstract
Objectives: An unprecedented wave of patients with acute respiratory failure due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) hit emergency departments (EDs) in Lombardy, starting in the second half of February 2020. This study describes the direct and indirect impacts of the SARS-CoV-2 outbreak on an urban major-hospital ED., Methods: Data regarding all patients diagnosed with COVID-19 presenting from February 1 to March 31, 2020, were prospectively collected, while data regarding non-COVID patients presenting within the same period in 2019 were retrospectively retrieved., Results: ED attendance dropped by 37% in 2020. Two-thirds of this reduction occurred early after the identification of the first autochthonous COVID-19 case in Lombardy, before lockdown measures were enforced. Hospital admissions of non-COVID patients fell by 26%. During the peak of COVID-19 attendance, the ED faced an extraordinary increase in: patients needing oxygen (+239%) or noninvasive ventilation (+725%), transfers to the intensive care unit (+57%), and in-hospital mortality (+309%), compared with the same period in 2019., Conclusions: The COVID-19 outbreak determined an unprecedented upsurge in respiratory failure cases and mortality. Fear of contagion triggered a spontaneous, marked reduction of ED attendance, and, presumably, some as yet unknown quantity of missed or delayed diagnoses for conditions other than COVID-19.
- Published
- 2021
- Full Text
- View/download PDF
37. Novel Coronavirus Disease (COVID-19) in Italian Patients: Gender Differences in Presentation and Severity.
- Author
-
Baiardo Redaelli M, Landoni G, Di Napoli D, Morselli F, Sartorelli M, Sartini C, Ruggeri A, Salonia A, Dagna L, and Zangrillo A
- Abstract
Background: In the first wave of the novel coronavirus (severe acute respiratory syndrome coronavirus 2) infections, Italy experienced a heavy burden of hospital admissions for acute respiratory distress syndromes associated with the novel coronavirus disease (COVID-19). Early evidence suggested that females are less affected than males., Objective: This study aimed to assess the gender-related differences in presentation and severity among COVID-19 patients admitted to IRCCS San Raffaele Hospital, Milan, Italy., Materials and Methods: This prospective observational study included all patients admitted to the hospital between February 25 and April 19, 2020, with a positive real-time reverse-transcriptase polymerase chain reaction for COVID-19. The following data were collected: date of admission, gender, age and details of intensive care unit admission and outcomes., Results: A total of 901 patients with COVID-19 were admitted to the hospital and provided consent for the study. Of these, 284 were female (31.5%). The percentage of admitted female patients significantly increased over time (25.9% of all admissions in the first half of the study period vs. 37.1% in the second half; P < 0.001). Females accounted for 14.4% of all COVID-19 intensive care unit admissions. There was no gender-based difference in the overall hospital mortality: 20.1% for females and 19.2% for males ( P = 0.8)., Conclusions: In our hospital, which was in the epicenter of the first wave of COVID-19 pandemic in Italy, female patients were few, presented late and were less critical than male patients., Competing Interests: There are no conflicts of interest., (Copyright: © 2020 Saudi Journal of Medicine & Medical Sciences.)
- Published
- 2021
- Full Text
- View/download PDF
38. Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study.
- Author
-
De Lorenzo R, Conte C, Lanzani C, Benedetti F, Roveri L, Mazza MG, Brioni E, Giacalone G, Canti V, Sofia V, D'Amico M, Di Napoli D, Ambrosio A, Scarpellini P, Castagna A, Landoni G, Zangrillo A, Bosi E, Tresoldi M, Ciceri F, and Rovere-Querini P
- Subjects
- Aftercare statistics & numerical data, Aged, COVID-19, Coronavirus Infections complications, Coronavirus Infections rehabilitation, Female, Follow-Up Studies, Humans, Male, Middle Aged, Pandemics, Pneumonia, Viral complications, Pneumonia, Viral rehabilitation, Cognitive Dysfunction epidemiology, Coronavirus Infections epidemiology, Dyspnea epidemiology, Malnutrition epidemiology, Pneumonia, Viral epidemiology, Stress Disorders, Post-Traumatic epidemiology
- Abstract
Data on residual clinical damage after Coronavirus disease-2019 (COVID-19) are lacking. The aims of this study were to investigate whether COVID-19 leaves behind residual dysfunction, and identify patients who might benefit from post-discharge monitoring. All patients aged ≥18 years admitted to the Emergency Department (ED) for COVID-19, and evaluated at post-discharge follow-up between 7 April and 7 May, 2020, were enrolled. Primary outcome was need of follow-up, defined as the presence at follow-up of at least one among: respiratory rate (RR) >20 breaths/min, uncontrolled blood pressure (BP) requiring therapeutic change, moderate to very severe dyspnoea, malnutrition, or new-onset cognitive impairment, according to validated scores. Post-traumatic stress disorder (PTSD) served as secondary outcome. 185 patients were included. Median [interquartile range] time from hospital discharge to follow-up was 23 [20-29] days. 109 (58.9%) patients needed follow-up. At follow-up evaluation, 58 (31.3%) patients were dyspnoeic, 41 (22.2%) tachypnoeic, 10 (5.4%) malnourished, 106 (57.3%) at risk for malnutrition. Forty (21.6%) patients had uncontrolled BP requiring therapeutic change, and 47 (25.4%) new-onset cognitive impairment. PTSD was observed in 41 (22.2%) patients. At regression tree analysis, the ratio of arterial oxygen partial pressure to fractional inspired oxygen (PaO2/FiO2) and body mass index (BMI) at ED presentation, and age emerged as independent predictors of the need of follow-up. Patients with PaO2/FiO2 <324 and BMI ≥33 Kg/m2 had the highest odds to require follow-up. Among hospitalised patients, age ≥63 years, or age <63 plus non-invasive ventilation or diabetes identified those with the highest probability to need follow-up. PTSD was independently predicted by female gender and hospitalisation, the latter being protective (odds ratio, OR, 4.03, 95% confidence interval, CI, 1.76 to 9.47, p 0.0011; OR 0.37, 95% CI 0.14 to 0.92, p 0.033, respectively). COVID-19 leaves behind physical and psychological dysfunctions. Follow-up programmes should be implemented for selected patients., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2020
- Full Text
- View/download PDF
39. [The IRCCS San Raffaele Hospital organizational model to assess the clinical documentation completeness and the appropriateness of hospitalization: the SVAD experience and the results of the three-year period 2018-2020.]
- Author
-
Di Napoli D, Bossi E, Gaetti G, Congiu P, Secchi M, Berzaghini S, Fiorella G, Stella A, Wysocka E, Villa G, and Ambrosio A
- Subjects
- Hospitals, Humans, Documentation standards, Hospitalization, Medical Records standards, Models, Organizational
- Abstract
According to the progressive increase in the number of medical records checked by the Agenzia di Tutela della Salute (ATS) of the Metropolitan City of Milan, the San Raffaele Hospital established a Unit supporting healthcare personnel in clinical documentation management. Therefore, in 2003 the Servizio Valutazione Appropriatezza della Documentazione clinica (SVAD), consisting of a nursing staff highly qualified in checking the appropriateness of clinical pathways, completeness and correctness of the clinical documentation and appropriate coding in the hospital discharge cards, was set up in the Health Directorate. Since 2018, the Service has seen an increase in resources, a re-organization and integration with the Operating Units. The aim of the article is to describe the introduction of a new organizational model and the results obtained, with reference to the quality self-control carried out for the ATS. In order to conduct a descriptive analysis of the trend, the sample data, required by the ATS in the three-year period 2018-2020, stratified by outcome and consequent percentage of reduction on the reimbursement of hospitalization, were considered. We observe an overall percentage increase in medical records without any reduction from 2018 to 2020, going from 84% to 94% (+ 10%); at the same time, there is a constant trend of medical records with complete curtailment between 2018 and 2019, while there is a reduction between 2019 and 2020, going from 4% to 2% (-2%). The positive results demonstrate the essential role of SVAD and consolidate an alternative career for nursing staff.
- Published
- 2020
40. Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency
- Author
-
Zangrillo A, Beretta L, Silvani P, Colombo S, Scandroglio AM, Dell’Acqua A, Fominskiy E, Landoni G, Monti G, Azzolini ML, Monaco F, Oriani A, Belletti A, Sartorelli M, Pallanch O, Saleh O, Sartini C, Nardelli P, Lombardi G, Morselli F, Scquizzato T, Frontera A, Ruggeri A, Scotti R, Assanelli A, Dagna L, Rovere-Querini P, Castagna A, Scarpellini P, Di Napoli D, Ambrosio A, Ciceri F, and Tresoldi M
- Abstract
At the end of 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak spread from China all around the world, causing thousands of deaths. In Italy, the hardest hit region was Lombardy, with the first reported case on 20 February 2020. San Raffaele Scientific Institute — a large tertiary hospital and research centre in Milan, Italy — was immediately involved in the management of the public health emergency. Since the beginning of the outbreak, the elective surgical activity of the hospital was rapidly reduced and large areas of the hospital were simultaneously reorganised to admit and assist patients with coronavirus disease 2019 (COVID-19). In addition, the hospital became the regional referral hub for cardiovascular emergencies in order to keep ensuring a high level of health care to non-COVID-19 patients in northern Italy. In a few days, a COVID-19 emergency department was created, improving the general ward capacity to a total number of 279 beds dedicated to patients with COVID-19. Moreover, the number of intensive care unit (ICU) beds was increased from 28 to 72 (54 of them dedicated to patients with COVID-19, and 18 to cardiology and cardiac surgery hub emergencies), both converting pre-existing areas and creating new high technology spaces. All the involved health care personnel were rapidly trained to use personal protection equipment and to manage this particular category of patients both in general wards and ICUs. Furthermore, besides clinical activities, continuously important research projects were carried out in order to find new strategies and more effective therapies to better face an unprecedented health emergency in Italy., Competing Interests: None declared.
- Published
- 2020
41. A rat model of acute kidney injury through systemic hypoperfusion evaluated by micro-US, color and PW-Doppler.
- Author
-
Iacobellis F, Segreto T, Berritto D, Nettuno F, Cozzolino S, Di Napoli D, Montella M, Natella R, Cappabianca S, Brunese L, and Grassi R
- Subjects
- Acute Kidney Injury physiopathology, Animals, Disease Models, Animal, Hypopharyngeal Neoplasms, Kidney blood supply, Kidney physiopathology, Male, Rats, Rats, Sprague-Dawley, Reproducibility of Results, Shock, Hemorrhagic physiopathology, Ultrasonography, Doppler, Color, Acute Kidney Injury diagnostic imaging, Shock, Hemorrhagic diagnostic imaging, Ultrasonography, Doppler methods
- Abstract
Aim: To create an animal model of acute renal ischemia induced by systemic hypoperfusion, controllable and reproducible to study, in real time, hemorrhagic shock changes with micro-imaging., Animals and Methods: Hemorrhagic shock was induced in rats activating a syringe pump setup to remove 1 mL/min of blood, through the femoral artery catheter. The withdrawal was continued until the mean arterial pressure (MAP) dropped to 25-30 mmHg. For the next 60 min, the MAP was maintained at a constant pressure value, by automatic pump infusion and withdrawal. Micro-ultrasound imaging was performed using the Vevo 2100 system with the MS250 transducer (13-24 MHz). Renal size, morphology and echogenicity were evaluated in B-mode. Renal blood flow was evaluated using color and PW-Doppler., Results: After 1 h of ischemia, B-mode images documented slight changes in kidney echogenicity. Color and PW-Doppler analysis showed a reduction in renal blood flow in kidneys during the hypoperfusion with a progressive and significant change from baseline values of resistive index (RI). At the histological evaluation, 60 min of hypoperfusion resulted in ischemic changes in the kidneys., Conclusions: The results of this experimental study encourage the use of the described model to study acute renal ischemia trough severe hypoperfusion. The histological data confirmed that the model was able to produce injury in renal parenchyma. It can be used to assess acute ischemic damage not only in the kidney but also in other organs by using all available dedicated small animals imaging techniques.
- Published
- 2019
- Full Text
- View/download PDF
42. Prevalence of Takayasu arteritis in young women with acute ischemic heart disease.
- Author
-
Cavalli G, Tomelleri A, Di Napoli D, Baldissera E, and Dagna L
- Subjects
- Acute Disease, Adult, Cardiovascular Agents therapeutic use, Chest Pain diagnosis, Chest Pain drug therapy, Female, Humans, Myocardial Ischemia diagnosis, Myocardial Ischemia drug therapy, Prevalence, Takayasu Arteritis diagnosis, Takayasu Arteritis drug therapy, Chest Pain epidemiology, Emergency Medical Services trends, Myocardial Ischemia epidemiology, Takayasu Arteritis epidemiology
- Abstract
Objectives: Takayasu arteritis (TA), a systemic vasculitis typically occurring in female patients aged ≤40, can affect coronary arteries and cause ischemic heart disease (IHD). In this study, we investigated the prevalence of TA in young women presenting with IHD in the Emergency Department., Methods: We evaluated hospital records of 158,860 consecutive female patients aged <40, who accessed the Emergency Department of our institution over 8 consecutive years (2007-2015). The prevalence of different etiologies of IHD was determined. Diagnosis of TA was established based on the 1990 ACR criteria., Results: Overall, 1950 women aged <40 presented to the Emergency Department with chest pain, dyspnea, palpitations, angina, heart failure, or cardiac arrest; 40 had acute IHD. The etiology was 'classic' atherosclerosis in 24 cases (60%), TA in 4 cases (10%), vasospasm and sympathomimetic drug abuse in 3 cases each (7.5%), coronary artery dissection and microvascular angina in 2 cases each (5%), Takotsubo and radiation-induced cardiomyopathy in 1 case each (2.5%)., Discussion: Although a diagnosis of TA is likely to be overlooked, TA is not infrequent in younger females presenting with acute IHD, a finding relevant to the diagnosis and management of these patients., (Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
43. Induction of VX2 para-renal carcinoma in rabbits: generation of animal model for loco-regional treatments of solid tumors.
- Author
-
Bimonte S, Leongito M, Piccirillo M, Tamma ML, Vallifuoco M, Bracco A, Mancini A, Di Napoli D, Castaldo S, Cozzolino S, Iacobellis F, Grassi R, Granata V, Lastoria S, Curley S, and Izzo F
- Abstract
Background: Animal models of para-renal cancer can provide useful information for the evaluation of tumor response to loco-regional therapy experiments in solid tumors. The aim of our study was to establish a rabbit para-renal cancer model using locally implanted VX2 tumors., Methods: In order to generate a rabbit model of para-renal cancer, we established four hind limb donor rabbits by using frozen VX2 tumor samples. Following inoculation, rabbits were monitored for appetite and signs of pain. Viable tumors appeared as palpable nodules within 2 weeks of inoculation. Tumor growth was confirmed in all rabbits by high-resolution ultrasound analysis and histology. Once tumor growth was established, hind limb tumors extraction was used for tumor line propagation and para-renal tumor creation. Twenty-one rabbit models bearing para-renal cancer were established by implanting VX2 tumor into the para-renal capsula. Tumors developed into discreet 2-3 cm nodules within 1-3 weeks of implantation. Serial renal ultrasonography follow-up, starting 1 week after tumor implantation, was performed. Two weeks after tumor implantation, rabbits were euthanized and tumors and other organs were collected for histopathology., Results: Tumor growth after VX2 tumor fragment implantation was confirmed in all rabbits by high-resolution ultrasound (US) imaging examinations of the para-renal regions and was measured with digital caliper. The para-renal injection of VX2 tumor fragments, achieved tumor growth in 100% of cases. All data were confirmed by histological analysis., Conclusions: We generated for the first time, a model of para-renal cancer by surgical tumor implantation of VX2 frozen tumor fragments into rabbit's para-renal region. This method minimizes the development of metastases and the use of non-necrotic tumors and will optimize the evaluation of tumor response to loco-regional therapy experiments.
- Published
- 2016
- Full Text
- View/download PDF
44. The Murine Model of Mucopolysaccharidosis IIIB Develops Cardiopathies over Time Leading to Heart Failure.
- Author
-
Schiattarella GG, Cerulo G, De Pasquale V, Cocchiaro P, Paciello O, Avallone L, Belfiore MP, Iacobellis F, Di Napoli D, Magliulo F, Perrino C, Trimarco B, Esposito G, Di Natale P, and Pavone LM
- Subjects
- Acetylglucosaminidase genetics, Animals, Echocardiography, Heart Failure diagnostic imaging, Mice, Mice, Inbred C57BL, Mice, Knockout, Mucopolysaccharidosis III complications, Disease Models, Animal, Heart Failure complications, Mucopolysaccharidosis III physiopathology
- Abstract
Mucopolysaccharidosis (MPS) IIIB is a lysosomal disease due to the deficiency of the enzyme α-N-acetylglucosaminidase (NAGLU) required for heparan sulfate (HS) degradation. The disease is characterized by mild somatic features and severe neurological disorders. Very little is known on the cardiac dysfunctions in MPS IIIB. In this study, we used the murine model of MPS IIIB (NAGLU knockout mice, NAGLU(-/-)) in order to investigate the cardiac involvement in the disease. Echocardiographic analysis showed a marked increase in left ventricular (LV) mass, reduced cardiac function and valvular defects in NAGLU(-/-) mice as compared to wild-type (WT) littermates. The NAGLU(-/-) mice exhibited a significant increase in aortic and mitral annulus dimension with a progressive elongation and thickening of anterior mitral valve leaflet. A severe mitral regurgitation with reduction in mitral inflow E-wave-to-A-wave ratio was observed in 32-week-old NAGLU(-/-) mice. Compared to WT mice, NAGLU(-/-) mice exhibited a significantly lower survival with increased mortality observed in particular after 25 weeks of age. Histopathological analysis revealed a significant increase of myocardial fiber vacuolization, accumulation of HS in the myocardial vacuoles, recruitment of inflammatory cells and collagen deposition within the myocardium, and an increase of LV fibrosis in NAGLU(-/-) mice compared to WT mice. Biochemical analysis of heart samples from affected mice showed increased expression levels of cardiac failure hallmarks such as calcium/calmodulin-dependent protein kinase II, connexin43, α-smooth muscle actin, α-actinin, atrial and brain natriuretic peptides, and myosin heavy polypeptide 7. Furthermore, heart samples from NAGLU(-/-) mice showed enhanced expression of the lysosome-associated membrane protein-2 (LAMP2), and the autophagic markers Beclin1 and LC3 isoform II (LC3-II). Overall, our findings demonstrate that NAGLU(-/-) mice develop heart disease, valvular abnormalities and cardiac failure associated with an impaired lysosomal autophagic flux.
- Published
- 2015
- Full Text
- View/download PDF
45. Biliverdin protects against liver ischemia reperfusion injury in swine.
- Author
-
Andria B, Bracco A, Attanasio C, Castaldo S, Cerrito MG, Cozzolino S, Di Napoli D, Giovannoni R, Mancini A, Musumeci A, Mezza E, Nasti M, Scuderi V, Staibano S, Lavitrano M, Otterbein LE, and Calise F
- Subjects
- Animals, Liver drug effects, Swine, Biliverdine therapeutic use, Liver metabolism, Reperfusion Injury drug therapy
- Abstract
Ischemia reperfusion injury (IRI) in organ transplantation remains a serious and unsolved problem. Organs that undergo significant damage during IRI, function less well immediately after reperfusion and tend to have more problems at later times when rejection can occur. Biliverdin has emerged as an agent that potently suppress IRI in rodent models. Since the use of biliverdin is being developed as a potential therapeutic modality for humans, we tested the efficacy for its effects on IRI of the liver in swine, an accepted and relevant pre-clinical animal model. Administration of biliverdin resulted in rapid appearance of bilirubin in the serum and significantly suppressed IRI-induced liver dysfunction as measured by multiple parameters including urea and ammonia clearance, neutrophil infiltration and tissue histopathology including hepatocyte cell death. Taken together, our findings, in a large animal model, provide strong support for the continued evaluation of biliverdin as a potential therapeutic in the clinical setting of transplantation of the liver and perhaps other organs.
- Published
- 2013
- Full Text
- View/download PDF
46. Unfolded protein response is not activated in the mucopolysaccharidoses but protein disulfide isomerase 5 is deregulated.
- Author
-
Villani GR, Chierchia A, Di Napoli D, and Di Natale P
- Subjects
- Alternative Splicing, Animals, Apoptosis, Brain metabolism, CHO Cells, Computational Biology methods, Cricetinae, DNA, Complementary metabolism, DNA-Binding Proteins metabolism, Fibroblasts metabolism, Humans, Mice, Mutation, Protein Disulfide-Isomerases chemistry, Regulatory Factor X Transcription Factors, Staurosporine pharmacology, Transcription Factors metabolism, X-Box Binding Protein 1, Gene Expression Regulation, Enzymologic, Mucopolysaccharidoses genetics, Protein Disulfide-Isomerases physiology, Unfolded Protein Response
- Abstract
Mucopolysaccharidoses (MPSs) are lysosomal storage diseases (LSDs) caused by defects in lysosomal enzymes involved in the catabolism of glycosaminoglycans. The pathogenesis of these disorders is still not completely known, although inflammation and oxidative stress appear to be common mechanisms, as in all LSDs. Recently, it was hypothesized that endoplasmic reticulum (ER) stress followed by an unfolded protein response (UPR) could be another common pathogenetic mechanism in LSDs. The aim of the present study was to verify if the UPR was elicited in the mucopolysaccharidoses and if the mechanism was MPS type- and mutation-dependent. To this end, we analyzed the UPR in vitro, in fibroblasts from patients with different types of mucopolysaccharidoses (MPS I, II, IIIA, IIIB, IVA) and in vivo, in the murine MPS IIIB model. In both cases we found no changes in mRNA levels of several UPR-related genes, such as the spliced or unspliced form of Xbp-1, Bip, Chop, Edem1, Edem2, Edem3. Therefore, we report here that the unfolded protein response of the ER is not triggered either in vitro or in vivo; accordingly, cytotoxicity assays indicated that affected fibroblasts are no more sensitive to apoptosis induction than normal cells. However, our results show that in most of the analyzed MPS fibroblasts the expression of a poorly known protein belonging to the family of the protein disulfide isomerases, namely Pdia5, is upregulated; here we discuss if its upregulation could be an early event of ER stress possibly related to the severity of the damage induced in the mutant proteins.
- Published
- 2012
- Full Text
- View/download PDF
47. Activation of stress kinases in the brain of mucopolysaccharidosis IIIB mice.
- Author
-
Cecere F, Di Domenico C, Di Napoli D, Boscia F, and Di Natale P
- Subjects
- Age Factors, Animals, Cells, Cultured, Cerebral Cortex embryology, Disease Models, Animal, Gene Expression Regulation physiology, Mice, Mice, Knockout, Mice, Mutant Strains, Mitogen-Activated Protein Kinase 3 metabolism, Mitogen-Activated Protein Kinase 8 metabolism, Oxidative Stress, Reactive Oxygen Species, p38 Mitogen-Activated Protein Kinases metabolism, Cerebral Cortex enzymology, Mitogen-Activated Protein Kinases metabolism, Mucopolysaccharidosis III enzymology, Neurons enzymology
- Abstract
The accumulation of heparan sulfate (HS) in lysosomes is the primary consequence of the enzyme defect (α-N-acetylglucosaminidase) in mucopolysaccharidosis type IIIB. This accumulation triggers a cascade of pathological events that progressively leads to CNS pathology. Here we examined the activation of the three major stress kinases in the neuronal tissue of a murine model of the disease. ERK1/2 was significantly higher in the cortex of 1-2-month-old affected animals compared with wild-type (Wt) littermates. Similarly, ERK1/2 was stimulated in neurons cultured from MPS IIIB mice. SAPK/JNK was also found to be activated in the cortex of 1-2-month-old affected animals compared with Wt subjects, and the same was found for cultured neurons. In contrast, the active form of p38MAPK was lower in the cortex of 1-month-old MPS IIIB mice compared with Wt animals, but no significant difference was found between the two p38MAPK analyzed in normal and affected neurons cultured in vitro. These data indicate the possible involvement of MAPK dysregulation in the early stage of MPS IIIB brain disease., (Copyright © 2011 Wiley-Liss, Inc.)
- Published
- 2011
- Full Text
- View/download PDF
48. Btk regulation in human and mouse B cells via protein kinase C phosphorylation of IBtkγ.
- Author
-
Janda E, Palmieri C, Pisano A, Pontoriero M, Iaccino E, Falcone C, Fiume G, Gaspari M, Nevolo M, Di Salle E, Rossi A, De Laurentiis A, Greco A, Di Napoli D, Verheij E, Britti D, Lavecchia L, Quinto I, and Scala G
- Subjects
- Adaptor Proteins, Signal Transducing, Agammaglobulinaemia Tyrosine Kinase, Alanine genetics, Amino Acid Substitution physiology, Animals, Carrier Proteins genetics, Cells, Cultured, Humans, Intracellular Signaling Peptides and Proteins, Mice, Mice, Knockout, Mutation, Missense physiology, Phosphorylation, Protein-Tyrosine Kinases antagonists & inhibitors, Serine genetics, Signal Transduction physiology, Carrier Proteins metabolism, Cells metabolism, Protein Kinase C metabolism, Protein-Tyrosine Kinases metabolism
- Abstract
The inhibitor of Bruton tyrosine kinase γ (IBtkγ) is a negative regulator of the Bruton tyrosine kinase (Btk), which plays a major role in B-cell differentiation; however, the mechanisms of IBtkγ-mediated regulation of Btk are unknown. Here we report that B-cell receptor (BCR) triggering caused serine-phosphorylation of IBtkγ at protein kinase C consensus sites and dissociation from Btk. By liquid chromatography and mass-mass spectrometry and functional analysis, we identified IBtkγ-S87 and -S90 as the critical amino acid residues that regulate the IBtkγ binding affinity to Btk. Consistently, the mutants IBtkγ carrying S87A and S90A mutations bound constitutively to Btk and down-regulated Ca(2+) fluxes and NF-κB activation on BCR triggering. Accordingly, spleen B cells from Ibtkγ(-/-) mice showed an increased activation of Btk, as evaluated by Y551-phosphorylation and sustained Ca(2+) mobilization on BCR engagement. These findings identify a novel pathway of Btk regulation via protein kinase C phosphorylation of IBtkγ.
- Published
- 2011
- Full Text
- View/download PDF
49. Worsening of cardiomyopathy using deflazacort in an animal model rescued by gene therapy.
- Author
-
Rotundo IL, Faraso S, De Leonibus E, Nigro G, Vitiello C, Lancioni A, Di Napoli D, Castaldo S, Russo V, Russo F, Piluso G, Auricchio A, and Nigro V
- Subjects
- Animals, Blotting, Western, Cardiomyopathies metabolism, Cricetinae, Dependovirus genetics, Echocardiography, Genetic Vectors, Male, Mesocricetus, Sarcoglycans genetics, Sarcoglycans metabolism, Cardiomyopathies drug therapy, Cardiomyopathies therapy, Genetic Therapy, Pregnenediones therapeutic use
- Abstract
We have previously demonstrated that gene therapy can rescue the phenotype and extend lifespan in the delta-sarcoglycan deficient cardiomyopathic hamster. In patients with similar genetic defects, steroids have been largely used to slow down disease progression. Aim of our study was to evaluate the combined effects of steroid treatment and gene therapy on cardiac function. We injected the human delta-sarcoglycan cDNA by adeno-associated virus (AAV) 2/8 by a single intraperitoneal injection into BIO14.6 Syrian hamsters at ten days of age to rescue the phenotype. We then treated the hamsters with deflazacort. Treatment was administered to half of the hamsters that had received the AAV and the other hamsters without AAV, as well as to normal hamsters. Both horizontal and vertical activities were greatly enhanced by deflazacort in all groups. As in previous experiments, the AAV treatment alone was able to preserve the ejection fraction (70±7% EF). However, the EF value declined (52±14%) with a combination of AAV and deflazacort. This was similar with all the other groups of affected animals. We confirm that gene therapy improves cardiac function in the BIO14.6 hamsters. Our results suggest that deflazacort is ineffective and may also have a negative impact on the cardiomyopathy rescue, possibly by boosting motor activity. This is unexpected and may have significance in terms of the lifestyle recommendations for patients.
- Published
- 2011
- Full Text
- View/download PDF
50. Serum MIP-1 alpha level: a biomarker for the follow-up of lentiviral therapy in mucopolysaccharidosis IIIB mice.
- Author
-
Di Natale P, Di Domenico C, and Di Napoli D
- Subjects
- Acetylglucosaminidase metabolism, Animals, Brain physiology, Disease Models, Animal, Disease Progression, Female, Follow-Up Studies, Male, Mice, Mice, Mutant Strains, Transgenes genetics, Acetylglucosaminidase genetics, Biomarkers blood, Chemokine CCL3 blood, Genetic Therapy, Lentivirus genetics, Mucopolysaccharidosis III blood, Mucopolysaccharidosis III genetics, Mucopolysaccharidosis III therapy
- Abstract
Mucopolysaccharidosis (MPS) IIIB is an inherited lysosomal storage disorder caused by deficiency of alpha-N-acetylglucosaminidase (NAGLU). The disease is characterized by mild somatic features and severe neurological involvement, with high mortality rates. Although some therapeutic approaches have been applied to the murine model of the disease, no effective therapy is available. Moreover, assessing therapeutic efficacy is challenged by the lack of markers to for progression and severity. In this study, we examined the effect of brain-directed lentiviral (LV) gene therapy on serum levels of macrophage inflammatory protein 1 alpha (MIP-1alpha) and brain-derived neurotrophic factor (BDNF) proteins in the murine model of MPS IIIB to identify novel serum biomarkers. The cytokine MIP-1alpha was elevated in MPS IIIB mouse serum, and following gene therapy, it was reduced to normal levels. For neurotrophin BDNF, the difference in serum levels between MPS IIIB and normal mice was not statistically significant; after LV gene therapy, an increase in protein was found in treated mice, although the values were not statistically significant. Our studies suggest MIP-1alpha as the first serum biomarker that could be used to monitor disease progression and treatment for MPS IIIB disease.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.